Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway

• 主要な著者: Rui Zhou (著者), Chuman Lin (著者), Yanzhen Cheng (著者), Xiaoyun Zhuo (著者), Qinghua Li (著者), Wen Xu (著者), Liang Zhao (著者), Li Yang (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2021-03-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Non-alcoholic fatty liver disease (NAFLD), ranging from non-alcoholic fatty liver to non-alcoholic steatohepatitis, can be prevalent in patients with type 2 diabetes mellitus (T2DM). However, no antidiabetic drug has been approved for the treatment of NAFLD in T2DM patients. Multiple daily injection...